Incyte Price to Book Ratio 2006-2021 | INCY

Historical price to book ratio values for Incyte (INCY) over the last 10 years. The current price to book ratio for Incyte as of October 20, 2021 is 4.92.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Incyte Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-20 65.65 4.93
2021-06-30 84.13 $13.32 6.32
2021-03-31 81.27 $12.41 6.55
2020-12-31 86.98 $11.90 7.31
2020-09-30 89.74 $10.92 8.22
2020-06-30 103.97 $10.75 9.67
2020-03-31 73.23 $8.93 8.20
2019-12-31 87.32 $12.02 7.26
2019-09-30 74.23 $11.25 6.60
2019-06-30 84.96 $10.46 8.12
2019-03-31 86.01 $9.73 8.84
2018-12-31 63.59 $9.03 7.04
2018-09-30 69.08 $8.47 8.15
2018-06-30 67.00 $8.16 8.21
2018-03-31 83.33 $7.68 10.85
2017-12-31 94.71 $7.72 12.27
2017-09-30 116.74 $8.33 14.01
2017-06-30 125.91 $4.99 25.21
2017-03-31 133.67 $4.72 28.31
2016-12-31 100.27 $2.22 45.14
2016-09-30 94.29 $1.97 47.98
2016-06-30 79.98 $1.58 50.58
2016-03-31 72.47 $1.22 59.63
2015-12-31 108.45 $0.92 118.27
2015-09-30 110.38 $0.48 231.31
2015-06-30 104.21 $0.31 340.33
2015-03-31 91.66 $-0.24 -383.84
2014-12-31 73.11 $-0.48 -153.05
2014-09-30 49.05 $-0.53 -92.44
2014-06-30 56.44 $-1.02 -55.57
2014-03-31 53.52 $-0.97 -55.19
2013-12-31 50.63 $-1.18 -42.73
2013-09-30 38.15 $0.18 213.13
2013-06-30 22.00 $-0.18 -121.08
2013-03-31 23.41 $-1.21 -19.40
2012-12-31 16.61 $-1.31 -12.67
2012-09-30 18.05 $-1.68 -10.76
2012-06-30 22.70 $-1.67 -13.60
2012-03-31 19.30 $-1.94 -9.93
2011-12-31 15.01 $-1.80 -8.36
2011-09-30 13.97 $-1.43 -9.75
2011-06-30 18.94 $-1.08 -17.52
2011-03-31 15.85 $-0.84 -18.87
2010-12-31 16.56 $-0.72 -23.03
2010-09-30 15.99 $-1.05 -15.19
2010-06-30 11.07 $-0.86 -12.89
2010-03-31 13.93 $-0.94 -14.74
2009-12-31 9.11 $-0.86 -10.58
2009-09-30 6.75 $-1.68 -4.01
2009-06-30 3.29 $-2.97 -1.11
2009-03-31 2.34 $-2.64 -0.89
2008-12-31 3.79 $-2.27 -1.67
2008-09-30 7.65 $-1.83 -4.19
2008-06-30 7.61 $-2.79 -2.73
2008-03-31 10.51 $-2.33 -4.51
2007-12-31 10.05 $-1.89 -5.33
2007-09-30 7.15 $-1.68 -4.26
2007-06-30 6.00 $-1.42 -4.22
2007-03-31 6.59 $-1.24 -5.30
2006-12-31 5.84 $-1.01 -5.78
2006-09-30 4.23 $-0.79 -5.36
2006-06-30 4.60 $-0.65 -7.05
2006-03-31 6.02 $-0.45 -13.33
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.458B $2.667B
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43